Mesenchymal stem cells-based therapies for severe ARDS with ECMO: a review

Area of Science:

• Critical Care Medicine
• Regenerative Medicine
• Pulmonology

Background:

• Acute respiratory distress syndrome (ARDS) is a major cause of respiratory failure in critically ill patients, associated with high mortality.
• Mesenchymal stem cell (MSC) therapy offers a potential treatment for ARDS, while extracorporeal membrane oxygenation (ECMO) serves as a life-support measure.
• The COVID-19 pandemic has highlighted the urgent need for effective ARDS treatments.

Purpose of the Study:

• To review the current status of combining extracorporeal membrane oxygenation (ECMO) with mesenchymal stem cell (MSC) therapy for ARDS.
• To identify the clinical challenges and future prospects of this combined therapeutic approach.

Main Methods:

• Literature review of studies investigating ECMO and MSC-based therapies for ARDS.
• Analysis of existing evidence on the efficacy and safety of combined treatments.
• Discussion of unresolved issues and future research directions.

Main Results:

• Some studies suggest that combining ECMO with MSC therapy yields better therapeutic effects for ARDS.
• Other research indicates that critical issues must be resolved before clinical application of this combination.
• The review synthesizes findings on the potential benefits and limitations of ECMO-MSC combination therapy.

Conclusions:

• The combination of ECMO and MSC therapy presents a potential strategy for treating ARDS.
• Further investigation is required to overcome existing clinical challenges and optimize this treatment.
• Future research should focus on addressing safety and efficacy concerns for successful clinical translation.